ASRS 2020: What Aviceda’s lead candidate AVD-104 may mean for dry AMD

Video

Derek Kunimoto, MD, JD, focuses on Aviceda's technology, which will aim to target various immune system responses that contribute to pathology associated with dry AMD.


Derek Kunimoto, MD, JD, focuses on Aviceda's technology, which will aim to target various immune system responses that contribute to pathology associated with dry AMD, in an interview with Sheryl Stevenson, Modern Retina's® group editorial director, during the virtual 2020 American Society of Retina Specialists (ASRS) annual meeting.

See more ASRS conference coverage here

Recent Videos
Marion Munk, MD, PhD, presenting slides
Marion Munk, MD, PhD, presenting slides
© 2024 MJH Life Sciences

All rights reserved.